An antithrombotic therapeutic strategy consisting of an OAC and dual antiplatelet therapy (DAPT; P2Y12 inhibitor ± aspirin) is recommended in AF patients undergoing PCI3. This evidence concerns the gene P2RY12 and atrial fibrillation.